IP Group (LON:IPO) Releases Quarterly Earnings Results

IP Group (LON:IPO) issued its quarterly earnings data on Tuesday. The company reported GBX 7.24 EPS for the quarter, Digital Look Earnings reports. IP Group had a net margin of 117.22% and a negative return on equity of 15.13%.

Here are the key takeaways from IP Group’s conference call:

• Reported full‑year NAV per share rose to £1.10 (up 13% YoY) driven by realizations and valuation gains, demonstrating tangible portfolio value growth.
• Recognised a fair value of £128m for long‑dated royalty/milestone rights from the Pfizer/Metsera obesity programs, providing meaningful upside while noting remaining clinical, regulatory and commercial risks.
• Returned capital via a £45m buyback in 2025 (retiring ~10% of shares at large discounts) and earmarked ~£30m for future buybacks, confirming buybacks are a primary tool when shares trade well below NAV.
• Portfolio momentum: companies raised >£900m of third‑party capital (up ~17% YoY) and several assets delivered strong exits or fundraising (e.g., Hinge Health, Monolith, Artios), increasing routes to future cash realizations.
• Despite progress, the market continues to value IP Group at a substantial discount to NAV (well over 50% at the time of the call), leaving the share price disconnected from reported intrinsic value and posing ongoing downside/market perception risk.

IP Group Trading Up 7.6%

Shares of IPO opened at GBX 52.99 on Tuesday. IP Group has a 1-year low of GBX 34.35 and a 1-year high of GBX 66.16. The company has a current ratio of 15.42, a quick ratio of 8.59 and a debt-to-equity ratio of 16.10. The firm’s 50-day moving average price is GBX 56.42 and its 200-day moving average price is GBX 57.52. The firm has a market capitalization of £468.11 million, a price-to-earnings ratio of -3.71 and a beta of 1.29.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank reaffirmed a “buy” rating and set a GBX 100 price target on shares of IP Group in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of GBX 100.

About IP Group

IP Group accelerates the impact of science for a better future. As the most active UK based, early-stage science investor, we develop and support some of the world’s most exciting businesses in deeptech, life sciences and cleantech (led by Kiko Ventures). Through Parkwalk, the UK’s largest growth EIS fund manager, we also back world-changing innovation emerging in leading universities and research institutions. Our specialist investment team combines sector expertise with an international approach.